Welcome to our dedicated page for Relmada Therapeutics news (Ticker: RLMD), a resource for investors and traders seeking the latest updates and insights on Relmada Therapeutics stock.
Relmada Therapeutics, Inc. develops clinical-stage therapies for oncology and central nervous system disorders. Company news centers on NDV-01, an intravesical sustained-release gemcitabine-docetaxel therapy being evaluated for non-muscle invasive bladder cancer, including clinical data, FDA feedback on registrational study design, and presentations at medical conferences.
Recurring updates also cover quarterly and annual financial results, business progress, healthcare conference participation, and financing activity tied to the company’s clinical development plans.
Relmada Therapeutics (Nasdaq: RLMD) appointed Bipin Dalmia, PhD, MBA as Chief Business Officer, reporting to CEO Sergio Traversa. He will lead corporate strategy, commercial planning and business development as the company advances NDV-01, a sustained-release intravesical therapy for non-muscle invasive bladder cancer (NMIBC).
Dalmia brings nearly 30 years of biopharma leadership, including 14 years at Ferring Pharmaceuticals, where he led the Uro-Oncology Franchise and the U.S. launch and global strategy for ADSTILADRIN, the first FDA-approved intravesical gene therapy for BCG-unresponsive NMIBC. According to Relmada, his background in NMIBC, portfolio strategy and transactions is expected to support the company’s long-term growth initiatives.
Relmada Therapeutics (Nasdaq: RLMD) plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss its financial results for the second quarter ended June 30, 2026, along with recent business progress.
According to Relmada, U.S. participants can dial 1-800-717-1738, international participants can dial 1-646-307-1865, and a webcast will be accessible via the Investors section of the company’s website, where a replay will also be available.
Relmada Therapeutics (Nasdaq: RLMD), a clinical-stage biotech focused on oncology and CNS disorders, announced its addition to the Russell 2000 and Russell 3000 indexes, effective after the U.S. market close on June 26, 2026.
These indexes track major U.S. companies and are widely used by institutional investors for index funds and performance benchmarks.
Relmada Therapeutics (Nasdaq: RLMD) appointed Michael Quirk, PhD, as Senior Advisor for its sepranolone program. He brings over 20 years of neuroscience drug discovery and development experience, including service as Chief Scientific Officer at Sage Therapeutics.
Sepranolone targets Prader-Willi syndrome and other CNS indications via GABAA receptor modulation.
Relmada Therapeutics (Nasdaq: RLMD) will participate in the Jefferies Global Healthcare Conference in New York from June 2-4, 2026. CEO Sergio Traversa and CFO Maged Shenouda will join a fireside chat on Thursday, June 4, 2026, at 12:50 PM ET.
A live webcast and 90-day replay will be available via the Relmada investor relations website, and management will hold one-on-one investor meetings scheduled through Jefferies.
Relmada Therapeutics (Nasdaq: RLMD) reported Q1 2026 results and a business update focused on NDV-01 in high-risk NMIBC.
NDV-01 12‑month Phase 2 data showed CR rates of 95% (any time) and 76% at 12 months; in BCG‑unresponsive patients, CR rates were 94% and 80%, with no progression to muscle‑invasive disease or radical cystectomies.
Relmada plans to file an NDV-01 IND and start the Phase 3 RESCUE program in mid‑2026, filed a provisional NDV‑01 patent expected to run to April 2047 if issued, and will present data at AUA2026. Q1 R&D was $8.1M, G&A $11.4M, net loss $19.1M, and cash was $234.0M, expected to fund operations through 2029.
Relmada Therapeutics (Nasdaq: RLMD) will report first quarter 2026 financial results and host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET. The company will discuss results for the quarter ended March 31, 2026 and provide updates on recent business and clinical progress.
Participant dial-in numbers and a webcast link are provided; a replay will be available in the Investors section of the Relmada website.
Relmada Therapeutics (Nasdaq: RLMD) will present two abstracts on NDV-01 at AUA2026 in Washington D.C., May 15-18, 2026. A 12-month Phase 2 update in high-risk NMIBC will be presented May 15, and a Phase 3 overview (RESCUE program) will appear in a Trials-in-Progress session May 17.
The company said the Phase 3 RESCUE registrational program remains on track to be initiated mid-2026. Exact presentation times and locations may change.
Relmada Therapeutics (Nasdaq: RLMD) reported strong Phase 2 NDV-01 data and completed a $160 million PIPE financing to fund development through 2029. Key clinical results showed a 95% CR rate at any time and a 76% durable CR at 12 months in high‑risk NMIBC.
The company is aligned with the FDA on two registrational pathways and plans to initiate the Phase 3 RESCUE program in mid‑2026, with IND clearance targeted the same period.
Relmada Therapeutics (Nasdaq: RLMD) will host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss fourth-quarter results for the period ended December 31, 2025 and recent business progress.
Participant dial-ins are provided for US and international callers, and a replay will be available in the Investors section of the Relmada website.